citalopram has been researched along with Phobic Disorders in 33 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Phobic Disorders: Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 9.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "The aim of the present study was to evaluate neuroendocrine and behavioural responses to a challenge with the selective serotonin (5-HT) reuptake inhibitor citalopram (Cit) in patients with social anxiety disorder (SAD)." | 9.11 | Citalopram challenge in social anxiety disorder. ( Aluoja, A; Maron, E; Shlik, J; Tru, I; Vasar, V, 2004) |
| "To examine the effects of long-term treatment with citalopram or clomipramine on subjective phobic symptoms in patients with panic disorder." | 9.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 8.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 5.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "The aim of the present study was to evaluate neuroendocrine and behavioural responses to a challenge with the selective serotonin (5-HT) reuptake inhibitor citalopram (Cit) in patients with social anxiety disorder (SAD)." | 5.11 | Citalopram challenge in social anxiety disorder. ( Aluoja, A; Maron, E; Shlik, J; Tru, I; Vasar, V, 2004) |
| "Short-term administration of GR205171 and citalopram alleviated social anxiety." | 5.11 | Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. ( Ahs, F; Appel, L; Bani, M; Bergström, M; Flyckt, K; Fredrikson, M; Furmark, T; Grohp, M; Jacobsson, E; Långström, B; Michelgård, A; Nilsson, LG; Pich, EM; Wahlstedt, K; Zancan, S, 2005) |
| "To examine the effects of long-term treatment with citalopram or clomipramine on subjective phobic symptoms in patients with panic disorder." | 5.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 4.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| " We sought to determine these thresholds by comparing, in a post hoc analysis, scores on the Clinical Global Impressions scale (CGI) and disorder-specific symptom severity rating scales from all available studies of the treatment of major depressive disorder, panic disorder, generalized anxiety disorder, and social anxiety disorder with the same medication (escitalopram)." | 4.83 | What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? ( Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2006) |
| "Escitalopram was started at 10 mg/day, then increased and maintained at 20 mg/day for 10 weeks at the end of which completers were randomly assigned to placebo or escitalopram for 9 additional weeks." | 2.73 | Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. ( Allen, A; Baker, B; Chaplin, WF; Dell'Osso, B; Hadley, S; Hollander, E, 2008) |
| "Escitalopram was generally well-tolerated." | 2.73 | An open-label trial of escitalopram in children and adolescents with social anxiety disorder. ( Isolan, L; Manfro, GG; Oswald, S; Pheula, G; Rohde, LA; Salum, GA, 2007) |
| "Citalopram treatment may benefit patients with primary social anxiety disorder and comorbid major depression, and it should be further studied in controlled trials." | 2.71 | Citalopram treatment of social anxiety disorder with comorbid major depression. ( Blanco, C; Campeas, R; Lewis-Fernandez, R; Liebowitz, MR; Lin, SH; Marshall, R; Sanchez-Lacay, JA; Schmidt, AB; Schneier, FR; Simpson, HB, 2003) |
| "Citalopram appears to be a safe and effective treatment for compulsive shopping disorder." | 2.71 | Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. ( Bullock, KD; Chuong, HW; Koran, LM; Smith, SC, 2003) |
| "Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder." | 2.71 | Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. ( Kasper, S; Loft, H; Nil, R; Stein, DJ, 2005) |
| "Escitalopram was well tolerated during double-blind treatment of generalized SAD, and only 2." | 2.71 | A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. ( Boulenger, JP; Dürr-Pal, N; Loft, H; Montgomery, SA; Nil, R, 2005) |
| "Citalopram was used on an open-label naturalistic basis in 22 social phobia patients presenting for treatment (40 mg daily for 12 weeks)." | 2.69 | Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. ( Bouwer, C; Stein, DJ, 1998) |
| "Escitalopram was effective in both younger and older patients, in male and female patients, and in patients with more and less severe social anxiety symptoms." | 1.32 | Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. ( Andersen, EW; Kasper, S; Lader, M; Nil, R; Stein, DJ, 2004) |
| "Citalopram was generally well-tolerated, and seven patients achieved responder status." | 1.31 | Citalopram for social phobia: a clinical case series. ( Marzol, PC; Pollack, MH; Sharma, SG; Simon, NM; Worthington, JJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.12) | 18.2507 |
| 2000's | 25 (75.76) | 29.6817 |
| 2010's | 4 (12.12) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pelissolo, A | 2 |
| Moukheiber, A | 1 |
| Ulbricht, CM | 1 |
| Rothschild, AJ | 1 |
| Lapane, KL | 1 |
| Baldwin, DS | 2 |
| Stein, DJ | 7 |
| Dolberg, OT | 2 |
| Bandelow, B | 2 |
| Muhtz, C | 1 |
| Agorastos, A | 1 |
| Kellner, M | 1 |
| Warwick, JM | 1 |
| Carey, PD | 1 |
| Cassimjee, N | 1 |
| Lochner, C | 1 |
| Hemmings, S | 1 |
| Moolman-Smook, H | 1 |
| Beetge, E | 1 |
| Dupont, P | 1 |
| Koch, HJ | 1 |
| Gehring, C | 1 |
| Atmaca, M | 2 |
| Kuloglu, M | 2 |
| Tezcan, E | 2 |
| Unal, A | 1 |
| Schneier, FR | 1 |
| Blanco, C | 1 |
| Campeas, R | 1 |
| Lewis-Fernandez, R | 1 |
| Lin, SH | 1 |
| Marshall, R | 1 |
| Schmidt, AB | 1 |
| Sanchez-Lacay, JA | 1 |
| Simpson, HB | 1 |
| Liebowitz, MR | 1 |
| Koran, LM | 1 |
| Chuong, HW | 1 |
| Bullock, KD | 1 |
| Smith, SC | 1 |
| Shlik, J | 1 |
| Maron, E | 1 |
| Tru, I | 1 |
| Aluoja, A | 1 |
| Vasar, V | 1 |
| Lader, M | 2 |
| Stender, K | 1 |
| Bürger, V | 1 |
| Nil, R | 4 |
| Vorob'eva, OV | 1 |
| Vasil'chikova, NV | 1 |
| Ustundag, B | 1 |
| Tunckol, H | 1 |
| Kasper, S | 2 |
| Andersen, EW | 1 |
| Loft, H | 2 |
| Furmark, T | 2 |
| Appel, L | 1 |
| Michelgård, A | 1 |
| Wahlstedt, K | 1 |
| Ahs, F | 1 |
| Zancan, S | 1 |
| Jacobsson, E | 1 |
| Flyckt, K | 1 |
| Grohp, M | 1 |
| Bergström, M | 1 |
| Pich, EM | 1 |
| Nilsson, LG | 1 |
| Bani, M | 1 |
| Långström, B | 2 |
| Fredrikson, M | 2 |
| Lele, M | 1 |
| Joglekar, A | 1 |
| Montgomery, SA | 1 |
| Dürr-Pal, N | 1 |
| Boulenger, JP | 1 |
| Andersen, HF | 1 |
| Alamy, S | 1 |
| Varia, I | 1 |
| Davidson, JR | 1 |
| Connor, KM | 1 |
| Dell'Osso, B | 1 |
| Hadley, S | 1 |
| Allen, A | 1 |
| Baker, B | 1 |
| Chaplin, WF | 1 |
| Hollander, E | 1 |
| Isolan, L | 1 |
| Pheula, G | 1 |
| Salum, GA | 1 |
| Oswald, S | 1 |
| Rohde, LA | 1 |
| Manfro, GG | 1 |
| Lepola, U | 4 |
| Leinonen, E | 4 |
| Koponen, H | 4 |
| Bouwer, C | 1 |
| Turtonen, J | 1 |
| Wade, A | 1 |
| Lehto, H | 1 |
| Van der Linden, G | 1 |
| van Heerden, B | 1 |
| Warwick, J | 1 |
| Wessels, C | 1 |
| van Kradenburg, J | 1 |
| Zungu-Dirwayi, N | 1 |
| Simon, NM | 1 |
| Sharma, SG | 1 |
| Worthington, JJ | 1 |
| Marzol, PC | 1 |
| Pollack, MH | 1 |
| Kosieradzki, PH | 1 |
| Ebeling, H | 1 |
| Moilanen, I | 1 |
| Linna, SL | 1 |
| Räsänen, E | 1 |
| Tillfors, M | 1 |
| Marteinsdottir, I | 1 |
| Fischer, H | 1 |
| Pissiota, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Efficacy of Escitalopram in the Treatment of Internet Addiction[NCT00565422] | Phase 4 | 31 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Cipralex® for Anxiety Disorders in Adolescents: Clinical and Physiological Changes Associated With Open Label, Flexible-dose Treatment[NCT01293838] | Phase 1 | 30 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| The Brain´s Plasticity and Change in Cellular Aging After Internet-delivered Cognitive Behavior Therapy for Social Anxiety Disorder[NCT02592564] | 50 participants (Actual) | Interventional | 2015-10-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
3 reviews available for citalopram and Phobic Disorders
| Article | Year |
|---|---|
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Topics: Anxiety Disorders; Citalopram; Diagnosis, Differential; Humans; Obsessive-Compulsive Disorder; Panic | 2008 |
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder, Major; | 2009 |
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Ment | 2006 |
18 trials available for citalopram and Phobic Disorders
| Article | Year |
|---|---|
The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome.
Topics: Adult; Anxiety Disorders; Bulimia; Citalopram; Depression; Feeding and Eating Disorders; Female; Hum | 2015 |
Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.
Topics: Adolescent; Adult; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Moclobemide; | 2002 |
Citalopram treatment of social anxiety disorder with comorbid major depression.
Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Phobic Disor | 2003 |
Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation.
Topics: Adult; Citalopram; Compulsive Behavior; Depressive Disorder, Major; Disruptive, Impulse Control, and | 2003 |
Citalopram challenge in social anxiety disorder.
Topics: Adolescent; Adult; Anxiety; Behavior; Citalopram; Cross-Over Studies; Double-Blind Method; Female; H | 2004 |
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study.
Topics: Adolescent; Adult; Aged; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Double-B | 2004 |
Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment.
Topics: Antidepressive Agents, Second-Generation; Catalase; Citalopram; Glutathione Peroxidase; Humans; Malo | 2004 |
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
Topics: Adult; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle A | 2005 |
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.
Topics: Adult; Anxiety; Cerebrovascular Circulation; Citalopram; Double-Blind Method; Female; Humans; Male; | 2005 |
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Huma | 2005 |
Escitalopram in specific phobia: results of a placebo-controlled pilot trial.
Topics: Adult; Avoidance Learning; Citalopram; Dose-Response Relationship, Drug; Double-Blind Method; Drug A | 2008 |
Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.
Topics: Adult; Citalopram; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Administration | 2008 |
An open-label trial of escitalopram in children and adolescents with social anxiety disorder.
Topics: Adolescent; Citalopram; Female; Humans; Male; Phobic Disorders; Psychiatric Status Rating Scales; Ps | 2007 |
An open-label trial of escitalopram in children and adolescents with social anxiety disorder.
Topics: Adolescent; Citalopram; Female; Humans; Male; Phobic Disorders; Psychiatric Status Rating Scales; Ps | 2007 |
An open-label trial of escitalopram in children and adolescents with social anxiety disorder.
Topics: Adolescent; Citalopram; Female; Humans; Male; Phobic Disorders; Psychiatric Status Rating Scales; Ps | 2007 |
An open-label trial of escitalopram in children and adolescents with social anxiety disorder.
Topics: Adolescent; Citalopram; Female; Humans; Male; Phobic Disorders; Psychiatric Status Rating Scales; Ps | 2007 |
Citalopram in the treatment of social phobia: a report of three cases.
Topics: Adult; Citalopram; Female; Humans; Male; Middle Aged; Phobic Disorders; Psychiatric Status Rating Sc | 1994 |
Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia.
Topics: Adult; Citalopram; Female; Humans; Male; Middle Aged; Phobic Disorders; Selective Serotonin Reuptake | 1998 |
Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial.
Topics: Adolescent; Adult; Aged; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Female; Humans; | 2000 |
Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adult; Brain; Citalopram; Female; Humans; Male; Phobic Disorders; Regional Blood Flow; Selective Ser | 2000 |
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.
Topics: Adult; Amygdala; Brain; Cerebral Cortex; Citalopram; Cognitive Behavioral Therapy; Female; Hippocamp | 2002 |
12 other studies available for citalopram and Phobic Disorders
| Article | Year |
|---|---|
Open-label treatment with escitalopram in patients with social anxiety disorder and fear of blushing.
Topics: Blushing; Citalopram; Fear; Humans; Phobic Disorders; Prospective Studies; Psychiatric Status Rating | 2013 |
Acute maniform reaction to a single dose of escitalopram in a social phobic patient--an atypical jitteriness syndrome?
Topics: Akathisia, Drug-Induced; Anxiety Disorders; Citalopram; Humans; Male; Mood Disorders; Phobic Disorde | 2009 |
Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Citalopram; Diagnostic and Statistical Manua | 2012 |
[Isolated fear of frogs and toads--a case of bufono-ranophobia].
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bufonidae; Citalopram; Comb | 2012 |
[The peculiarities of panic disorders determined by gender dimorphism].
Topics: Antidepressive Agents, Second-Generation; Beta Rhythm; Citalopram; Electroencephalography; Female; F | 2004 |
Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Diagnostic and Statis | 2004 |
Escitalopram for social anxiety disorder.
Topics: Citalopram; Humans; Phobic Disorders; Research Design; Selective Serotonin Reuptake Inhibitors; Stat | 2005 |
[Citalopram in the treatment of panic disorders and school phobia in children and adolescents].
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Female; Humans; Male; Panic Disorder; Phobic D | 1994 |
Citalopram in the treatment of early-onset panic disorder and school phobia.
Topics: Adolescent; Child; Citalopram; Female; Finland; Humans; Male; Panic Disorder; Phobic Disorders; Sele | 1996 |
Citalopram for social phobia: a clinical case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Female; Humans; Male; Middle Aged; Phob | 2001 |
Citalopram in social phobia.
Topics: Adolescent; Citalopram; Humans; Male; Phobic Disorders; Selective Serotonin Reuptake Inhibitors | 2001 |
Somatically expressed psychological distress and alexithymia in adolescence--reflecting unbearable emotions?
Topics: Adolescent; Affective Symptoms; Child; Citalopram; Dissociative Disorders; Domestic Violence; Emotio | 2001 |